Nateglinide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Nateglinide

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Nateglinide
ATC code	A10BX03 (WHO)
Pharmacokinetic data
Protein binding	98%
Elimination half-life	1.5 hours
Identifiers
IUPAC name 3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
CAS Number	105816-04-4
PubChem CID	60026
DrugBank	APRD00593
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H27NO3
Molar mass	317.423 g/mol

WikiDoc Resources for Nateglinide
Articles
Most recent articles on Nateglinide Most cited articles on Nateglinide Review articles on Nateglinide Articles on Nateglinide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nateglinide Images of Nateglinide Photos of Nateglinide Podcasts & MP3s on Nateglinide Videos on Nateglinide
Evidence Based Medicine
Cochrane Collaboration on Nateglinide Bandolier on Nateglinide TRIP on Nateglinide
Clinical Trials
Ongoing Trials on Nateglinide at Clinical Trials.gov Trial results on Nateglinide Clinical Trials on Nateglinide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nateglinide NICE Guidance on Nateglinide NHS PRODIGY Guidance FDA on Nateglinide CDC on Nateglinide
Books
Books on Nateglinide
News
Nateglinide in the news Be alerted to news on Nateglinide News trends on Nateglinide
Commentary
Blogs on Nateglinide
Definitions
Definitions of Nateglinide
Patient Resources / Community
Patient resources on Nateglinide Discussion groups on Nateglinide Patient Handouts on Nateglinide Directions to Hospitals Treating Nateglinide Risk calculators and risk factors for Nateglinide
Healthcare Provider Resources
Symptoms of Nateglinide Causes & Risk Factors for Nateglinide Diagnostic studies for Nateglinide Treatment of Nateglinide
Continuing Medical Education (CME)
CME Programs on Nateglinide
International
Nateglinide en Espanol Nateglinide en Francais
Business
Nateglinide in the Marketplace Patents on Nateglinide
Experimental / Informatics
List of terms related to Nateglinide

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs and is sold by Novartis.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the ß cells. This depolarizes the ß cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

External links

• Starlix - website of the manufacturer.
• How Nateglinide Works - website of the manufacturer.

Template:WikiDoc Sources